collaboration

Merck KGaA, Nerviano Enter License Agreement for PARP1 Inhibitor NMS-293

Abpro Licenses HER2-Targeteing Bispecific Antibody to Celltrion

Foundation Medicine, Day One Biopharmaceuticals to Develop CDx for Tovorafenib

Tempus, Children's Oncology Group Expand Genomic Testing Access for Pediatric Cancer Patients

Biocytogen Pharmaceuticals, Guangzhou FineImmune Biotechnology Ink Cell Therapy Partnership

Virogin Biotech, MD Anderson Ink Collaboration to Study Oncolytic Viruses

ITM, BAMF Health Partner to Advance Infrastructure for Delivering Radionuclide Treatments

BostonGene, Mass General Hospital Cancer Center Form Research Alliance

Indivumed, CellPhenomics Partner on Cancer Drug Target Research

Syapse, Genesis Research Partner to Offer Expanded Oncology Real-World Evidence Services

Ideaya Reaches Milestone in Deal With GSK for Pol Theta Helicase Program

Erasca, MD Anderson Cancer Center Partner to Study ERK, SHP2 Inhibitors

GSK Waives Rights to Ideaya's MAT2A Inhibitor IDE397

Personalis, BC Cancer Partner on Study of ctDNA MRD Tests for Colorectal, Pancreatic Cancers

Clarified Precision Medicine, VieCure Partner to Make Precision Oncology Expertise More Accessible

GSK, Mersana Therapeutics Ink $100M Option Agreement for Antibody-Drug Conjugate

Becton Dickinson, Labcorp Collaborate for Flow Cytometry-Based Companion Diagnostics

GenomOncology, Congenica Team up to Develop Precision Oncology Dx Platform

Exact Sciences Partners With West German Study Group to Validate MRD Test in Breast Cancer

Context Therapeutics, Menarini Group Collaborate on Phase I/II Breast Cancer Combo Trial